Oral Presentation | Aidea Pharma's Novel Integrase Inhibitor ACC017 Tablets Phase I/II Study Selected for Oral Presentation at the 26th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs

International Attention—Aitribond® SPRINT 96-Week Study Results Receive High Praise from International AIDS Experts

Reshaping the Future! 96-Week Study of Aitribond® Sparks Heated Discussion at IAS 2025

GOOD NEWS| Chinese Innovative Drug Brings New Hope to Africa's Fight Against AIDS: Aidea Pharma's Aitribond® Tablets Approved for Sale in Zanzibar.

Dr. Paula Munderi, Chief Scientific Officer of UNAIDS, Visits Aidea Pharma

Five Clinical Studies of Ainuomiti Tablets Selected for Presentation at IAS 2025 - The 13th International AIDS Society Conference on HIV Science in Kigali, Rwanda

Aidea Pharma Deeply Involved! New National Guidelines for anti-HIV Drug Resistance Research Released — Joining Forces to Strengthen the Fight Against HIV

"Dual Advantages of Efficacy and Safety!" Real-World Data on Ainuovirine Regimen Highlights China's Achievements in Tokyo

Ainuomiti Tablets Sparks Heated Discussions at APACC Tokyo, Japan